Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial.

• Tác giả: Giulia Benevolo, Carola Boccomini, Catello Califano, Tommaso Caravita di Toritto, Anna Castiglione, Federica Cavallo, Annarita Conconi, Luigi Curreli, Daniela Dessi, Daniela Drandi, Martina Ferrante, Simone Ferrero, Roberto Freilone, Gianluca Gaidano, Donato Mannina, Michele Merli, Federico Monaco, Gerardo Musuraca, Giuseppe Pietrantuono, Francesca Gaia Rossi, Roberto Sartori, Monica Tani, Patrizia Tosi, Marzia Varettoni, Nicoletta Villivà
• Ngôn ngữ: eng
• Ký hiệu phân loại: 272.3 Persecutions of Waldenses and Albigenses
• Thông tin xuất bản: England : British journal of haematology , 2025
• Bộ sưu tập: NCBI
• ID: 59761

Tóm tắt

This multicentre phase II study Fondazione Italiana Linfomi (FIL)-bortezomib plus rituximab plus bendamustine (BRB) tested a combination of bendamustine (90 mg/m